When is RhoGAM administered to a pregnant woman who is Rh negative?

When is RhoGAM administered to a pregnant woman who is Rh negative?

• A. Weekly during the ninth month, because this is her third pregnancy.
• B. Within 72 hours after delivery if the infant is found to be Rh positive.
• C. During the second trimester if an amniocentesis indicates a problem.
• D. To her infant immediately after delivery if the Coomb's test is positive.

Answer: (B)

RhoGAM, or Rh immunoglobulin, is administered to Rh-negative pregnant women primarily to prevent sensitization to Rh-positive blood from the fetus, which can occur during pregnancy or delivery. The correct scenario for its administration is indeed within 72 hours after delivery if the infant is found to be Rh positive. This is critical because if an Rh-negative mother becomes sensitized to Rh-positive blood, it can lead to serious complications in current or future pregnancies, such as hemolytic disease of the newborn. Administering RhoGAM during this period is effective in preventing the mother's immune system from developing antibodies against Rh-positive blood, thereby protecting subsequent pregnancies. The timing is essential; administering the immunoglobulin within 72 hours ensures that any potential sensitization from the delivery is mitigated. The other options, while they may seem reasonable, do not align with standard protocols for RhoGAM administration. Weekly administration during the ninth month isn't routine practice; RhoGAM is typically given at 28 weeks in anticipation of delivery for high-risk cases. Administration during the second trimester, specifically tied to amniocentesis results, does not follow standard protocol and is only indicated in specific circumstances. Administering RhoGAM to

RhoGAM, or Rh immunoglobulin, is administered to Rh-negative pregnant women primarily to prevent sensitization to Rh-positive blood from the fetus, which can occur during pregnancy or delivery. The correct scenario for its administration is indeed within 72 hours after delivery if the infant is found to be Rh positive. This is critical because if an Rh-negative mother becomes sensitized to Rh-positive blood, it can lead to serious complications in current or future pregnancies, such as hemolytic disease of the newborn.

Administering RhoGAM during this period is effective in preventing the mother's immune system from developing antibodies against Rh-positive blood, thereby protecting subsequent pregnancies. The timing is essential; administering the immunoglobulin within 72 hours ensures that any potential sensitization from the delivery is mitigated.

The other options, while they may seem reasonable, do not align with standard protocols for RhoGAM administration. Weekly administration during the ninth month isn't routine practice; RhoGAM is typically given at 28 weeks in anticipation of delivery for high-risk cases. Administration during the second trimester, specifically tied to amniocentesis results, does not follow standard protocol and is only indicated in specific circumstances. Administering RhoGAM to